This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Weinstock-Guttman, B Articles by Rudick, R Search for Related Content PubMed PubMed Citation Articles by Weinstock-Guttman, B Articles by Rudick, R Social Bookmarking                         What's this?

Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis

Baird MS Center, The Jacobs Neurological Institute, Buffalo, NY, USA, bweinstock-guttman{at}kaleidahealth.org

M Baier

Department of Neurology, Clinical Neurophysiology Laboratory, Buffalo General Hospital, Buffalo, NY, USA

R Stockton

Cooper Institute, Golden, CO, USA

A Weinstock

Cooper Institute, Golden, CO, USA

T Justinger

Baird MS Center, The Jacobs Neurological Institute, Buffalo, NY, USA

F Munschauer

Baird MS Center, The Jacobs Neurological Institute, Buffalo, NY, USA

C Brownscheidle

Baird MS Center, The Jacobs Neurological Institute, Buffalo, NY, USA

J Williams

Cooper Institute, Golden, CO, USA

E Fisher

Mellen Center, Cleveland Clinic, Cleveland, OH, USA

D Miller

Mellen Center, Cleveland Clinic, Cleveland, OH, USA

R Rudick

Mellen Center, Cleveland Clinic, Cleveland, OH, USA

Background: Pattern reversal visual evoked potentials (PRVEPs) have a well-documented role in diagnosis of multiple sclerosis (MS), but their value as a visual function surrogate remains controversial. Methods: We evaluated PRVEP in 37 patients with MS who were participating in a long-term follow-up study following a phase III trial of interferon b-1a (A vonex®). Patients were examined to determine the Kurtzke Extended Disability Status Score (EDSS), multiple sclerosis functional composite (MSFC), contrast letter acuity (CLA), and had cranial MRI scans to determine whole brain atrophy (BPF). PRVEP was evaluated for P100 latency, amplitude, and waveform morphology. Two summary scores were created: for Score A, abnormal latencies, morphologies, and amplitudes of each individual eye were added; for Score B, abnormal latencies, morphologies, and amplitude ratio between eyes was determined. Sixteen patients in this group also had PRVEP at the time they enrolled in the clinical trial, eight years previously. Results: A t the follow-up exam, over 75% of patients had abnormal PVEP parameters while visual acuity (VA) was abnormal only in 59%. Increased PRVEP latency over the eight-year period correlated with deterioration assessed by EDSS (P = 0.006), BPF (P = 0.0001), and MSFC (P = 0.0041). Score A was significantly correlated with EDSS, BPF, C LA, cognitive function, and quality of life assessed with the Sickness Impact profile. No correlation was seen with the MSFC. Conclusions: The results indicate that PRVEP measures MS-related patho logy, and can provide not only diagnostic but also prognostic information during evaluation of MS patients.

Key Words: multiple sclerosis • pattern reversal visual evoked potentials • visual acuity

Multiple Sclerosis, Vol. 9, No. 5, 529-534 (2003)
DOI: 10.1191/1352458503ms935rr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E M Mowry, M J Loguidice, A B Daniels, D A Jacobs, C E Markowitz, S L Galetta, M L Nano-Schiavi, G R Cutter, M G Maguire, and L J Balcer Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity J. Neurol. Neurosurg. Psychiatry, July 1, 2009; 80(7): 767 - 772. [Abstract] [Full Text] [PDF]

				V Pueyo, J Martin, J Fernandez, C Almarcegui, J Ara, C Egea, L Pablo, and F Honrubia Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis Multiple Sclerosis, June 1, 2008; 14(5): 609 - 614. [Abstract] [PDF]

				L. J. Balcer, S. L. Galetta, P. A. Calabresi, C. Confavreux, G. Giovannoni, E. Havrdova, M. Hutchinson, L. Kappos, F. D. Lublin, D. H. Miller, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis Neurology, April 17, 2007; 68(16): 1299 - 1304. [Abstract] [Full Text] [PDF]

				J. M. Ness, D. Chabas, A. D. Sadovnick, D. Pohl, B. Banwell, B. Weinstock-Guttman, and for the International Pediatric MS Study Group Clinical features of children and adolescents with multiple sclerosis Neurology, April 17, 2007; 68(16_suppl_2): S37 - S45. [Abstract] [Full Text] [PDF]

				L Leocani, M Rovaris, F M Boneschi, S Medaglini, P Rossi, V Martinelli, S Amadio, and G Comi Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study J. Neurol. Neurosurg. Psychiatry, September 1, 2006; 77(9): 1030 - 1035. [Abstract] [Full Text] [PDF]